Impact of PET Acquisition Durations on Image Quality and Lesion Detectability in Whole-body Ga-PSMA PET-MRI

Overview

Journal EJNMMI Res

Date 2017 Feb 8

PMID 28168589

Citations 15

Authors

Benjamin Noto

Florian Buther

Katharina Auf der Springe

Nemanja Avramovic

Walter Heindel

Michael Schafers

Thomas Allkemper

Lars Stegger

Affiliations

Soon will be listed here.

Abstract

Background: While Ga-PSMA PET-MRI might be superior to PET-CT with regard to soft tissue assessment in prostate cancer evaluation, it is also known to potentially introduce additional PET image artefacts. Therefore, the impact of PET acquisition duration and attenuation data on artefact occurrence, lesion detectability, and quantification was investigated. To this end, whole-body PET list mode data from 12 patients with prostate cancer were acquired 1 h after injection of 2 MBq/kg [Ga]HBED-CC-PSMA on a hybrid PET-MRI system. List mode data were further transformed into data sets representing 300, 180, 90, and 30 s acquisition duration per bed position. Standard attenuation and scatter corrections were performed based on MRI-derived attenuation maps, complemented by emission-based attenuation data in areas not covered by MRI. A total of 288 image data sets were reconstructed with varying acquisition durations for emission and attenuation data with and without scatter and prompt gamma correction, and further analysed regarding image quality and diagnostic performance.

Results: Decreased PET acquisition durations resulted in a significantly increased incidence of halo artefacts around kidneys and bladder, decreased lesion detectability and lower SUV as well as markedly lower arm attenuation values: Halo artefacts were present in 5 out of 12 cases at 300-s duration, in 6 at 180 s, in 10 at 90 s, and in 11 cases at 30 s. Using attenuation data of the 300 s scans restored artefact occurrence to the original 300-s level. Prompt gamma correction only led to small improvements in terms of artefact occurrence and size. Of the 141 detected lesions in the 300-s images one lesion was not detected at 180 s, 28 at 90 s, and 64 at 30 s. Using the 300-s attenuation map decreased non-detectability of lesions to zero at 180 s, 9 at 90 s, and 52 at 30 s. Attenuation maps at 90 and 30 s demonstrated markedly lower mean arm attenuation values (0.002 cm) than those at 300 s (0.084 cm), and 180 s (0.062 cm).

Conclusions: Short acquisition durations of less than 3 minutes per bed position result in unacceptable image artefacts and decreased diagnostic performance in current whole-body Ga-PSMA PET-MRI and should be avoided. Increased image noise and imperfections in generated attenuation maps were identified as a paramount cause for image degradation.

Citing Articles

Improved Positron Emission Tomography Quantification: Evaluation of a Maximum-Likelihood Scatter Scaling Algorithm.

Overbeck N, Ahangari S, Conti M, Panin V, Azam A, Kurbegovic S Diagnostics (Basel). 2024; 14(11).

PMID: 38893602 PMC: 11172368. DOI: 10.3390/diagnostics14111075.

Negative predictive value of PSMA PET scan for lymph node staging in patients undergoing robotic radical prostatectomy and pelvic lymph node dissection.

Adiyat K, Pooleri G, Cherian D, Gopalan Nair Santhamma S, Ravichandran K, Sundaram S Int Urol Nephrol. 2023; 55(6):1453-1457.

PMID: 37086333 DOI: 10.1007/s11255-023-03595-0.

Normal Skeletal Standardized Uptake Values Obtained from Quantitative Single-Photon Emission Computed Tomography/Computed Tomography: Time-Dependent Study on Breast Cancer Patients.

Nautiyal A, Jha A, Mithun S, Sawant V, Jadhav R, Khairnar K Indian J Nucl Med. 2022; 36(4):398-411.

PMID: 35125758 PMC: 8771070. DOI: 10.4103/ijnm.ijnm_47_21.

PET/MRI in prostate cancer: a systematic review and meta-analysis.

Evangelista L, Zattoni F, Cassarino G, Artioli P, Cecchin D, Dal Moro F Eur J Nucl Med Mol Imaging. 2020; 48(3):859-873.

PMID: 32901351 PMC: 8036222. DOI: 10.1007/s00259-020-05025-0.

Ga-PSMA-11 PET/MRI: determining ideal acquisition times to reduce noise and increase image quality.

Murthy V, Smith R, Tao D, Lawhn-Heath C, Korenchan D, Larson P EJNMMI Phys. 2020; 7(1):54.

PMID: 32844310 PMC: 7447708. DOI: 10.1186/s40658-020-00322-x.

References

Akamatsu G, Ikari Y, Nishida H, Nishio T, Ohnishi A, Maebatake A . Influence of Statistical Fluctuation on Reproducibility and Accuracy of SUVmax and SUVpeak: A Phantom Study. J Nucl Med Technol. 2015; 43(3):222-6. DOI: 10.2967/jnmt.115.161745. View

Paulus D, Quick H, Geppert C, Fenchel M, Zhan Y, Hermosillo G . Whole-Body PET/MR Imaging: Quantitative Evaluation of a Novel Model-Based MR Attenuation Correction Method Including Bone. J Nucl Med. 2015; 56(7):1061-6. PMC: 4894503. DOI: 10.2967/jnumed.115.156000. View

Partovi S, Kohan A, Gaeta C, Rubbert C, Vercher-Conejero J, Jones R . Image quality assessment of automatic three-segment MR attenuation correction vs. CT attenuation correction. Am J Nucl Med Mol Imaging. 2013; 3(3):291-9. PMC: 3627525. View

Buther F, Vehren T, Schafers K, Schafers M . Impact of Data-driven Respiratory Gating in Clinical PET. Radiology. 2016; 281(1):229-38. DOI: 10.1148/radiol.2016152067. View

Gaertner F, Beer A, Souvatzoglou M, Eiber M, Furst S, Ziegler S . Evaluation of feasibility and image quality of 68Ga-DOTATOC positron emission tomography/magnetic resonance in comparison with positron emission tomography/computed tomography in patients with neuroendocrine tumors. Invest Radiol. 2013; 48(5):263-72. DOI: 10.1097/RLI.0b013e31828234d0. View

Afshar-Oromieh A, Malcher A, Eder M, Eisenhut M, Linhart H, Hadaschik B . PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging. 2012; 40(4):486-95. DOI: 10.1007/s00259-012-2298-2. View

Conti M, Eriksson L . Physics of pure and non-pure positron emitters for PET: a review and a discussion. EJNMMI Phys. 2016; 3(1):8. PMC: 4894854. DOI: 10.1186/s40658-016-0144-5. View

Pfister D, Porres D, Heidenreich A, Heidegger I, Knuechel R, Steib F . Detection of recurrent prostate cancer lesions before salvage lymphadenectomy is more accurate with (68)Ga-PSMA-HBED-CC than with (18)F-Fluoroethylcholine PET/CT. Eur J Nucl Med Mol Imaging. 2016; 43(8):1410-7. DOI: 10.1007/s00259-016-3366-9. View

Afshar-Oromieh A, Haberkorn U, Schlemmer H, Fenchel M, Eder M, Eisenhut M . Comparison of PET/CT and PET/MRI hybrid systems using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience. Eur J Nucl Med Mol Imaging. 2013; 41(5):887-97. DOI: 10.1007/s00259-013-2660-z. View

10.

Chen Y, Lisok A, Chatterjee S, Wharram B, Pullambhatla M, Wang Y . [(18)F]Fluoroethyl Triazole Substituted PSMA Inhibitor Exhibiting Rapid Normal Organ Clearance. Bioconjug Chem. 2016; 27(7):1655-62. PMC: 5516890. DOI: 10.1021/acs.bioconjchem.6b00195. View

11.

Ceci F, Uprimny C, Nilica B, Geraldo L, Kendler D, Kroiss A . (68)Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate?. Eur J Nucl Med Mol Imaging. 2015; 42(8):1284-94. DOI: 10.1007/s00259-015-3078-6. View

12.

Prasad V, Steffen I, Diederichs G, Makowski M, Wust P, Brenner W . Biodistribution of [(68)Ga]PSMA-HBED-CC in Patients with Prostate Cancer: Characterization of Uptake in Normal Organs and Tumour Lesions. Mol Imaging Biol. 2016; 18(3):428-36. DOI: 10.1007/s11307-016-0945-x. View

13.

Nuyts J, Bal G, Kehren F, Fenchel M, Michel C, Watson C . Completion of a truncated attenuation image from the attenuated PET emission data. IEEE Trans Med Imaging. 2012; 32(2):237-46. DOI: 10.1109/TMI.2012.2220376. View

14.

Bostwick D, Pacelli A, Blute M, Roche P, Murphy G . Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer. 1998; 82(11):2256-61. DOI: 10.1002/(sici)1097-0142(19980601)82:11<2256::aid-cncr22>3.0.co;2-s. View

15.

Pomper M, Musachio J, Zhang J, Scheffel U, Zhou Y, Hilton J . 11C-MCG: synthesis, uptake selectivity, and primate PET of a probe for glutamate carboxypeptidase II (NAALADase). Mol Imaging. 2003; 1(2):96-101. DOI: 10.1162/15353500200202109. View

16.

Sahlmann C, Meller B, Bouter C, Ritter C, Strobel P, Lotz J . Biphasic ⁶⁸Ga-PSMA-HBED-CC-PET/CT in patients with recurrent and high-risk prostate carcinoma. Eur J Nucl Med Mol Imaging. 2015; 43(5):898-905. DOI: 10.1007/s00259-015-3251-y. View

17.

Giesel F, Cardinale J, Schafer M, Neels O, Benesova M, Mier W . (18)F-Labelled PSMA-1007 shows similarity in structure, biodistribution and tumour uptake to the theragnostic compound PSMA-617. Eur J Nucl Med Mol Imaging. 2016; 43(10):1929-30. PMC: 4969351. DOI: 10.1007/s00259-016-3447-9. View

18.

Rahbar K, Weckesser M, Huss S, Semjonow A, Breyholz H, Schrader A . Correlation of Intraprostatic Tumor Extent with ⁶⁸Ga-PSMA Distribution in Patients with Prostate Cancer. J Nucl Med. 2016; 57(4):563-7. DOI: 10.2967/jnumed.115.169243. View

19.

Afshar-Oromieh A, Avtzi E, Giesel F, Holland-Letz T, Linhart H, Eder M . The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2014; 42(2):197-209. PMC: 4315487. DOI: 10.1007/s00259-014-2949-6. View

20.

Verburg F, Pfister D, Heidenreich A, Vogg A, Drude N, Voo S . Extent of disease in recurrent prostate cancer determined by [(68)Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score. Eur J Nucl Med Mol Imaging. 2015; 43(3):397-403. DOI: 10.1007/s00259-015-3240-1. View